Intensity Therapeutics(INTS) - 2024 Q1 - Quarterly Results

Exhibit 99.1 Intensity Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update Shelton, CT, May 9, 2024 – Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, announces first quarter 2024 financial results and provides a corporate u ...